Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
about
Multiple myelomaVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceEnoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomideAdverse effects of thalidomide administration, in patients with myeloma multiplex?Acquired activated protein C resistance and thrombosis in multiple myeloma patientsWaldenstrom macroglobulinemiaImpairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.Thalidomide and immunomodulatory drugs in the treatment of cancer.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Treatment of multiple myeloma: an emphasis on new developments.Thalidomide and its analogues in the treatment of Multiple MyelomaThalidomide in multiple myeloma: past, present and future.Maintenance therapy in multiple myeloma.Modern treatment options for elderly patients with multiple myeloma.Drug repurposing in oncology--patient and health systems opportunities.Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple MyelomaMatrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway.Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?153Sm: its use in multiple myeloma and report of a clinical experience
P2860
Q24655964-8935A68D-33C5-4A4D-98FE-16248E7CFD04Q27008491-7AAC4C3D-275F-41EE-B019-1F1721F9FEADQ28199907-9797CDD3-BE98-4329-B30C-12908E071A6AQ33669639-CBFD1218-9CBA-49FE-A33C-2E47D17A8281Q35024872-801B5849-CCD1-4845-8E2B-7835953DAC3BQ35097328-D9D15033-B18F-4182-9F43-FF7DE82DF472Q35157385-85131E30-737B-4C01-ADDE-60E0CDBF2091Q35848146-FE3F63AA-14DA-423A-B0CC-EDEED0098814Q35863370-D038A607-9304-4889-BBC2-33BCEA3BF8C0Q36040871-F26278F8-7657-4FD3-810A-84F4D36B5930Q36171864-1A8097FA-0737-4330-9AF6-88B3502A1BB0Q36381565-3EBE2A05-8882-455A-A695-F84C84779D5BQ36438215-95D694EB-80EA-43B2-A935-90558324568AQ36444523-F1413DC8-915D-4AC3-BF74-5AC1919084DFQ36616493-E7B8D66E-25FC-4F69-AA24-B64DA9CCF5DFQ36754178-F8372B89-5934-4B5D-A022-34F81B0F3BA4Q37189281-AD06C249-BC3B-4ECA-9F60-AD8EC80BB8B6Q38611707-F03E0E4D-1B6F-45CE-B907-5D3C969AA5A5Q40406392-862D99E5-2CD5-4113-97F9-55013CB2E204Q41370609-3529CC9C-2D76-4248-B18D-E54A11C57FF1Q43042845-161950DB-823B-4E0A-A6D6-E16819DE6965Q45128205-91666625-EEE4-4388-87AC-0EF822CAE327Q45245750-AC2C8E72-6E23-49DE-8C38-066D11ACA331Q45252391-5F21C948-44FE-45ED-92C2-144D5ADD3642Q46634193-CEDE56CC-3769-4401-856D-C094D73E0CA1Q46726016-11471371-FDE5-47EE-A071-C97424AD9A12Q46946161-B4661F61-A57C-4BAA-AB46-14B165149BC0Q57904857-3691135E-99E9-4E27-B93C-E9BFB94BA263Q58449064-7D1F95DF-F157-41DD-8226-CBC8C25CC067
P2860
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@ast
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@en
type
label
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@ast
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@en
prefLabel
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@ast
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@en
P356
P1476
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
@en
P2093
Athanasios Anagnostopoulos
Donna Weber
P304
P356
10.1200/JCO.2003.07.200
P407
P577
2003-12-01T00:00:00Z